Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of DTaP-IPV-Hep B-PRP-T vaccine vs Infanrix hexa
2011-004455-39Phase 3
- Sponsor
- Sanofi
- Start
- Apr 2012
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of hexaxim in diphtheria, Tetanus, pertussis and 3 more (4 arms), sponsored by Sanofi. Primary endpoint: Primary immunogenicity endpoints at 1 month after third dose.
02
Drugs
hexaxim
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2011-004455-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004455-39.